917 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Recruiting Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Condition: Small Cell Lung Cancer
Intervention: Drug: G1T28 + Topotecan
22 Recruiting Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Conditions: Carcinoma, Non-Small-Cell Lung;   ErbB Receptors
Intervention: Drug: Afatinib
23 Not yet recruiting Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Condition: ALK-positive Non-small Cell Lung Cancer
Interventions: Drug: Ceritinib;   Radiation: Stereotactic ablative body radiation
24 Recruiting Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Endostar;   Drug: Changchun marina;   Drug: cisplatin;   Drug: Taxol;   Drug: parapl
25 Not yet recruiting LIquid BIopsies in Lung Cancer (LIBIL)
Condition: Carcinoma, Non-small Cell Lung
Intervention:
26 Not yet recruiting Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Condition: ALK-positive Advanced NSCLC
Interventions: Drug: Crizotinib;   Drug: Pembrolizumab
27 Not yet recruiting AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Condition: Stage IB-IIIA Non-small Cell Lung Carcinoma, With a Centrally Confirmed, Common Sensitising EGFR Mutations
Interventions: Drug: AZD9291 80 mg/40 mg;   Drug: Placebo AZD9291 80 mg/40 mg
28 Recruiting Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Device: PET scan imaging
29 Recruiting Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel + Plinabulin (DP);   Drug: Docetaxel (D)
30 Not yet recruiting Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Other: Placebo
31 Recruiting AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Conditions: Lung Cancer;   Targeted Therapy
Intervention: Drug: AZD9291
32 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
33 Not yet recruiting Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Drug: Selumetinib
34 Not yet recruiting Echocardiography for RILI Prediction
Condition: NSCLC
Intervention:
35 Recruiting A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Condition: EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Interventions: Drug: ASP8273 Capsules;   Drug: ASP8273 Capsules A
36 Recruiting SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer;   Large Cell Neuroendocrine Carcinoma
Intervention: Drug: SC-002
37 Recruiting G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer
Interventions: Drug: G1T28 + carboplatin/ etoposide;   Drug: Placebo + carboplatin/ etoposide
38 Recruiting Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Crizotinib
39 Not yet recruiting A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Glioblastoma Multiforme;   Melanoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Renal Cell Carcinoma
Intervention: Drug: DSP-7888 Dosing Emulsion
40 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years